Replies to post #159636 on Biotech Values

[DonShimoda]

Considering the Eyegate Ph3 trial only matched SOC, I'm wondering if XOMA will eventual run a trial in anterior uveitis?

XOMA—NIH starts phase-1/2 trial of Gevokicumab in non-infectious anterior scleritis

WALTHAM, MA, Apr 09, 2013 (Marketwired via COMTEX) -- EyeGate Pharma announces that the topline results from their Phase III study of EGP-437, a corticosteroid formulation, in Anterior Uveitis patients demonstrates that two iontophoretic treatments of EGP-437 achieved the same response rate as the positive control, prednisolone acetate 1% ophthalmic suspension administered as multiple daily eyedrops, the current standard of care.http://www.marketwatch.com/story/eyegates-egp-437-matches-the-standard-of-cares-response-rate-in-phase-iii-study-in-patients-with-anterior-uveitis-2013-04-09